Clinical trials: Advanced Leiomyosarcoma
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
This phase II/III trial compares the effect of the combination treatment with olaparib and temozolomide to trabectedin or pazopanib (two of the most common chemotherapy drugs used as usual approach) in patients with uterine…
- Conditions
- Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
- Trial name
- NCT05432791
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 145 sites in United States, Puerto Rico
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Leiomyosarcoma, Liposarcoma
Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
This study is designed to test the safety and efficacy of the combination of lenvatinib, a drug that can inhibit the growth of supplying vessels around the tumors, and eribulin, a chemotherapy drug that targets the cancer cell…
- Conditions
- Leiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult, Advanced Cancer
- Trial name
- LEADER (NCT03526679)
- Testing
- Eribulin, Lenvatinib
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Advanced and/or Metastatic Sarcoma
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
The goal of this clinical research study is to learn if the combination of durvalumab and tremelimumab can help to control sarcoma. The safety of this drug combination will also be studied. This is an investigational study.
- Trial name
- NCT02815995
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Liposarcoma or Leiomyosarcoma
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
The purpose of this study is to evaluate whether overall survival for the trabectedin group is superior to the dacarbazine group for patients with advanced L-sarcoma (liposarcoma or leiomyosarcoma).
- Trial name
- NCT01343277
- Testing
- Trabectedin, Dacarbazine
- Where
- 88 sites in United States, Australia and 2 more
- Volunteers
- 579 people
- Sponsor
- Janssen Research & Development, LLC